Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) have been assigned an average recommendation of “Hold” from the ten analysts that are presently covering the stock. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $85.21.

A number of research firms have issued reports on CRL. Jefferies Group LLC reissued a “buy” rating on shares of Charles River Laboratories Intl. in a research note on Thursday, March 16th. Evercore ISI raised shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $86.50 target price for the company in a research note on Wednesday, January 4th.

Shares of Charles River Laboratories Intl. (NYSE:CRL) traded up 0.95% on Monday, hitting $89.34. The stock had a trading volume of 180,874 shares. Charles River Laboratories Intl. has a one year low of $67.20 and a one year high of $91.57. The stock has a market cap of $4.23 billion, a PE ratio of 27.69 and a beta of 0.99. The company’s 50 day moving average is $88.56 and its 200 day moving average is $81.11.

Charles River Laboratories Intl. (NYSE:CRL) last posted its earnings results on Tuesday, February 14th. The medical research company reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.11 by $0.10. The firm earned $466.80 million during the quarter, compared to analyst estimates of $441.64 million. Charles River Laboratories Intl. had a net margin of 9.05% and a return on equity of 25.75%. Charles River Laboratories Intl.’s revenue was up 31.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.00 EPS. Equities research analysts predict that Charles River Laboratories Intl. will post $5.06 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at http://www.watchlistnews.com/brokerages-set-charles-river-laboratories-intl-inc-crl-price-target-at-85-21/1206165.html.

In other Charles River Laboratories Intl. news, insider William D. Barbo sold 1,900 shares of the business’s stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $87.90, for a total transaction of $167,010.00. Following the sale, the insider now directly owns 22,224 shares in the company, valued at approximately $1,953,489.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Davide Molho sold 11,717 shares of the business’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $90.00, for a total transaction of $1,054,530.00. Following the sale, the insider now owns 28,266 shares in the company, valued at $2,543,940. The disclosure for this sale can be found here. Insiders have sold a total of 85,932 shares of company stock worth $7,472,459 over the last 90 days. 2.30% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Envestnet Asset Management Inc. increased its stake in Charles River Laboratories Intl. by 41.8% in the fourth quarter. Envestnet Asset Management Inc. now owns 1,785 shares of the medical research company’s stock worth $135,000 after buying an additional 526 shares during the period. Bessemer Group Inc. increased its stake in Charles River Laboratories Intl. by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after buying an additional 43 shares during the period. Tower Research Capital LLC TRC bought a new stake in Charles River Laboratories Intl. during the third quarter worth approximately $181,000. Tyers Asset Management LLC bought a new stake in Charles River Laboratories Intl. during the fourth quarter worth approximately $188,000. Finally, Massmutual Trust Co. FSB ADV bought a new stake in Charles River Laboratories Intl. during the fourth quarter worth approximately $199,000. Institutional investors own 95.32% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.